Upcoming Presentations, Stock Price Movements, and Patent Challenge Settlements - Research Report on Johnson & Johnson, Alexion,

     Upcoming Presentations, Stock Price Movements, and Patent Challenge
    Settlements - Research Report on Johnson & Johnson, Alexion, Intuitive
                       Surgical, Medivation, and Impax

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 6, 2013

NEW YORK, December 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Intuitive
Surgical, Inc. (NASDAQ: ISRG), Medivation Inc. (NASDAQ: MDVN), and Impax
Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Johnson & Johnson Research Report

On December 3, 2013, Janssen Research & Development, LLC (Janssen), part of
the Janssen Pharmaceutical Companies of Johnson & Johnson (Johnson & Johnson),
announced that new data involving its novel oral anticoagulant XARELTO
(rivaroxaban) is scheduled to be presented at the 55th American Society of
Hematology (ASH) Annual Meeting and Exposition in New Orleans, Los Angeles,
from December 7, 2013 to December 10, 2013. Janssen reported that notable
presentations include Statin Use Was Associated With a Non-Significant
Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and
Einstein-PE, which will take place on December 7, 2013, 5:30 p.m. to 7:30 p.m.
CST, at Hall E (Ernest N. Morial Convention Center); Performance Of The
Simplified PESI Score In Patients With Pulmonary Embolism Treated With
Rivaroxaban Or Standard Therapy, which will also take place on December 7,
2013, 5:30 p.m. to 7:30 p.m. CST, at Hall E (Ernest N. Morial Convention
Center); and A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial
Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy
Subjects By Andexanet Alfa (PRT064445), An Antidote For FXa Inhibitors, to be
presented on December 9, 2013 6:00 p.m. to 8:00 p.m. CST. at Hall E (Ernest N.
Morial Convention Center). The Full Research Report on Johnson & Johnson -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Alexion Pharmaceuticals, Inc. Research Report

On December 3, 2013, Alexion Pharmaceuticals, Inc.'s (Alexion) stock declined
1.32%, ending the day at $122.16. Over the previous three trading sessions,
shares of Alexion gained 0.76% compared to the Nasdaq Composite which declined
0.19% during the same period. The Full Research Report on Alexion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4619_ALXN

--

Intuitive Surgical, Inc. Research Report

On December 3, 2013, Intuitive Surgical, Inc.'s (Intuitive Surgical) stock
declined 0.71%, ending the day at $372.81. Over the previous three trading
sessions, shares of Intuitive Surgical declined 1.38% compared to the Nasdaq
Composite which declined 0.19% during the same period. The Full Research
Report on Intuitive Surgical, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/5f98_ISRG

--

Medivation Inc. Research Report

On December 3, 2013, Medivation, Inc. (Medivation) and Astellas Pharma Inc.
(Astellas) announced enrollment of the first patient in a global Phase 3
clinical trial, PROSPER, which will evaluate the safety and efficacy of
enzalutamide in patients with non-metastatic (often referred to as M0)
castration-resistant prostate cancer (CRPC). According to the Company, no
prescription medicine is specifically approved for the treatment of patients
with non-metastatic CRPC in the US. David Hung, M.D., President and CEO of
Medivation, said, "PROSPER targets an important patient population as we and
Astellas look to advance the development of enzalutamide further upstream in
the prostate cancer treatment paradigm. The initiation of this trial
underscores our commitment to develop enzalutamide as a potential treatment
for those touched by this disease." The Full Research Report on Medivation
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4277_MDVN

--

Impax Laboratories Inc. Research Report

On December 3, 2013, Impax Laboratories Inc. (Impax) announced that the
Company has entered into an agreement with Purdue Pharma L.P. to settle all
outstanding patent litigation related to Impax's generic version of the
currently marketed, reformulated OxyContin. Impax reported that it will have
the right to market a specified number of bottles of its generic OxyContin,
contingent upon the Company receiving final approval from the US Food and Drug
Administration (FDA) on its Abbreviated New Drug Application (ANDA) for
generic OxyContin or to launch a specified number of bottles of an authorized
generic version of OxyContin if Impax does not have final ANDA approval, in
each case starting January 1, 2016 under the terms of the agreement. The Full
Research Report on Impax Laboratories Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/4c54_IPXL

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.